4.4 Article

Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients Clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia

期刊

JOURNAL OF CLINICAL LIPIDOLOGY
卷 5, 期 3, 页码 S1-S8

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacl.2011.04.003

关键词

Familial hypercholesterolemia; LDL receptor; Apheresis; Cascade screening; Heterozygous; Heterozygote; Homozygous; Homozygote

资金

  1. Abbott Laboratories
  2. American Diabetes Association
  3. American Heart Association
  4. AstraZeneca
  5. Bristol-Myers Squibb
  6. diaDexus
  7. GlaxoSmithKline
  8. Kowa Pharmaceuticals
  9. Merck Co.
  10. National Institutes of Health
  11. Novartis
  12. Roche/Genentech
  13. Sanofi-Synthelabo
  14. Takeda Pharmaceuticals
  15. Isis Pharmaceuticals
  16. Amarin
  17. ISIS-Genzyme Corporation
  18. Regeneron
  19. Daiichi Sankyo
  20. Hoffman LaRoche
  21. Merck Schering Plough
  22. Spirocor
  23. Genzyme Corporation
  24. Aegerion Pharmaceuticals
  25. Genzyme
  26. Kaneka Pharma America LLC

向作者/读者索取更多资源

The familial hypercholesterolemias (FH) are a group of genetic defects resulting in severe elevations of blood cholesterol levels and increased risk of premature coronary heart disease. FH is among the most commonly occurring congenital metabolic disorders. FH is a treatable disease. Aggressive lipid lowering is necessary to achieve the target LDL cholesterol reduction of at least 50% or more. Even greater target LDL cholesterol reductions may be necessary for FH patients who have other CHD risk factors. Despite the prevalence of this disease and the availability of effective treatment options, FH is both underdiagnosed and undertreated, particularly among children. Deficiencies in the diagnosis and treatment of FH indicate the need for greatly increased awareness and understanding of this disease, both on the part of the public and of healthcare practitioners. This document provides recommendations for the screening, diagnosis and treatment of FH in pediatric and adult patients developed by the National Lipid Association Expert Panel on Familial Hypercholesterolemia. This report goes beyond previously published guidelines by providing specific clinical guidance for the primary care clinician and lipid specialist with the goal of improving care of patients with FH and reducing their elevated risk for CUD. (C) 2011 National Lipid Association. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据